Alliance Growers Corp. (CSE:ACG, FWB:1LA, OTCQB:ALGWF) (“Alliance Growers” or “the Company) reports that the Company has entered into a Binding Letter of Intent, expanding its opportunity in West Africa from a 10 acre farm-in sub permit announced on June 26, 2019, to securing the rights to cultivate country wide, allowing Alliance to offer “10 acre farm out parcels” to other cannabis companies, as well as operating its own 10 acre farms
By way of the Binding LOI with Green Ocean Organics Ltd., the Company will control the Permit that allows Alliance Growers to cultivate, process, package and export all CBD, medical cannabis, extracted oils and related pharmaceutical products in an African country, which will be announced in 1st quarter 2020 pre the planting period of April 2020. The initial acreage granted is 50 acres for 2020, increasing on a 5-year Ministry agreement.
Extensive Due Diligence and All-encompassing Approach
Alliance Growers previously announced on June 26, 2019 that the Company had negotiated a farm-in agreement for an initial 10 leased acres requiring an investment of an estimated CAD$1.6 Million payable over the first full year of cultivation, producing an estimated potential annual net return of CAD$5.1 Million based on current forecasted costs and a significant discount to EU sales prices, to be conservative.
Since then, the Company has performed extensive due diligence, learning from the study and observation of other companies who have invested in Africa. We aim to be successful due to our all-encompassing approach. We start with working with the government to secure certification from the World Health Organization and the International Narcotics Control Board to assure the ability to export the product to countries that allow import of medical cannabis. The Company will sponsor the Ministry approved program to GACP, GMP and GDP certify all products grown and exported from the country with our German off-take partners.
Terms of the Binding LOI
The Binding LOI is between Alliance Growers, and Green Ocean Organics Ltd. (GOO), a private arms-length company, and a private African company, Global Medicinals SL Ltd & Partners (GM), and its major shareholder (KP).
GM holds, from the country’s Minister of Public Health, in consultation with the Minister of State and the Minister for the Interior, Safety, Decentralization, Current and Religious Affairs, a permit (the “Permit”) for the exploration, cultivation, production, storage, transportation and exportation of seeds and medicinal plants containing THC, CBD and their derivatives. GM and GOO have signed an agreement granting GOO the rights to develop, or otherwise commercialise the Permit. GOO will assist Alliance Growers in developing the Permit for the cultivation, production, harvesting, processing, marketing and export of cannabis specifically for medicinal and scientific purposes.
Subject to the completion of a Definitive Agreement, KP, the Major Shareholder of GM, and Timothy Rogers the major shareholder of GOO have agreed to sell and transfer to Alliance Growers 70% shares of GM on the terms and conditions of the LOI in consideration of the issuance of 25,000,000 common shares of Alliance Growers equal to $2,500,000, at a deemed value of 10c per share.
Targeting Revenue in Q3 2020
The first crop will be planted in late March or early April 2020 with the intention of harvesting the crop in or about October 2020. 15,000 cannabis seeds will be planted on each 10-acre lot provided to Alliance Growers, requiring an investment of an estimated CAD$1.6 Million payable over the first full year of cultivation, Concurrently, the Company will initially develop processing facilities for supplying extracted oil to be completed by the fall of 2020 at an estimated cost of $500,000 which will be 50% funded by African investors. Future products are expected to include dried flower, biomass and 1st phase extracted oils and resin, depending upon customer requirements and market development, with the target market focus being European pharmaceutical.
By way of acquisition of 70% of GM, Alliance Growers will receive 70% of the proceeds from each harvest, with 30% being mandatory national content under the terms of the Permit. In addition, Alliance Growers plans to offer sub-permit acreage each year to other medical cannabis companies seeking to grow low cost, high margin EU GMP certified product for export to their own customers on a managed cultivation or self-managed contract.
Commenting on securing this Permit opportunity, Dennis Petke, President and CEO of Alliance Growers stated, “Our nine months of due diligence and fact-checking has paid off, allowing us to secure a tremendous opportunity in Africa. We developed our approach to this opportunity in large part by learning from the trials and tribulations of others over the last two years. This is the first opportunity that has met the criteria we searched for in an international medical cannabis opportunity: low cost jurisdiction, partners with operational expertise on the ground, and experts in the application and approval for German certification of medical cannabis combined with a ready-market. We are extremely fortunate to have funders from the US, Canada and the UK interested in funding this 2020 revenue opportunity as well as obtaining sub-permit farm-in acreages. In addition to medical cannabis, we are very excited to be able to add an Agro-Parma Permit and provide Plant Based Medicine beyond cannabis. Enthusiasm towards this opportunity is reflected by the fact that some Directors have personally provided funds over the past 6 months to bring the project to contractual fruition. Management is committed to making 2020 a turn-around year for Alliance Growers, with the intent of benefiting all stakeholders.
Entitled to Grant Sub Permits
Under this agreement, Alliance Growers is entitled to grant sub-permits to other medicinal cannabis companies within their allocated acreage. These companies can sell their product independently, or they can be integrated into the Alliance Growers sales chain, but any product must meet the minimum standards for cultivation of cannabis established by the Company.
Ready Market with Off-take German Partners
The exclusive Permit has been secured through a GM, private African company, enabling Alliance Growers to grow, process, package and export CBD, extracted oils, medical cannabis and related pharmaceutical products from the country. Through this Permit, the Company expects and aims to be the lowest cost, high volume, quality certified raw material producer from an INCB compliant country in Africa to the EU medical marijuana market. The agreement includes an off-take agreement with GM’s German partners to purchase the bulk of the product produced. The remaining product will be sold into the international marketplace at competitive prices that is expected to yield significant profit. The geographic location is ideal, with the requisite sunshine and rainfall, tested and suitable soils, plus natural water readily available. Labour and taxes have been set in all the locations at some of the lowest levels seen globally, and logistics are secure and transparent.
Option to Acquire Agro-Pharma Permit
In addition to the Binding LOI for cannabis cultivation, Alliance Growers has first right of refusal to secure additional land in Africa under an Agro-Pharma permit, with an emphasis on Psilocybin for medical purposes. Modern Medicine now tends to use the active ingredients of plants rather than the whole plants where the phytochemicals may be synthesised, compounded or otherwise transformed to make pharmaceuticals. These ingredients, formulated for medical use as well as health food and sports supplements, will complement our cannabis platform with economic benefits realized under a cost sharing model. The Company is in the process of negotiation terms with GOO regarding territory, consideration to be paid, operational responsibilities and cost sharing.
International Compliance and Quality Control Testing
Only products grown under the auspices of an accredited certification body, with importing Government supervisions in a country recognized by the International Narcotics Control Board as being compliant, will be considered for purchase by EU medical cannabis buyers. Testing of all products for export will be conducted post-harvest and approved pre-export. Alliance Growers is currently in negotiations with a US company with a patented cannabis testing technology for compliance and for quality control. Most companies that offer testing services do not have a patented process and may find themselves in violation of these patents. This is what will give Alliance Growers the leading edge on cannabis testing with the exclusive rights to market and provide testing services in Canada with their technology. We will also be able to utilize the technology on favourable terms with our International operations.
Economic Development
In entering into this agreement, Alliance Growers recognizes that the country in which the business will be undertaken, as with most potentially emerging nations, is focused on “economic development.” To that end, Alliance Growers is intent upon using local labour, not only for the manual labour required on the land, but also in such areas such as security and day to day management. It is the Company’s hope that this project will provide both a return on investment for shareholders and assist the country in pursuing local economic development.
“Africa hasn’t developed better agricultural programs yet because lessons needed to be learned and attitudes need to change in order for compliance and certification to enable best practice cultivation. We have taken our time developing programs to start in 3 chosen and supportive West African countries, and our team is truly international, highly qualified, ethical and supportive of our aims in West Africa.” Winifred Boyah, General Manager Global Medicinals SL Limited.
“The climate, the labor, the vast internal resource means that Guinea is perfectly placed in 2020 to step away from the past and produce high quality regulated cultivated products for Europe and North American Health supplement and pharmaceutical markets. There is a new African business model, one which highlights compliance, regulation, security, transparency, partnership and that is what we are doing in Guinea with Green Ocean Organics”. Diallo Abdrahmane. General Manager Global Medicinals Guinea Limited.
“There is a reason why Cannabis hasn’t been grown and exported successfully from developing nations to the wider regulated pharmaceutical market, and that is down to the dated business transactions carried out by companies who don’t understand the developing world. Exploiting the potential of the natural resource from a developing nation needs to be a partnership in 2020, where the agreements, finance, ownership and business plan are transparent. That is where Green Ocean Organics sits, and that is what has been embraced by our partners in Africa on all levels.” Timothy Rogers, CEO, Green Ocean Organics Ltd.
Financing in conjunction with Agreement
The Company is in advanced discussions with several groups from the US, Canada and the UK interested in funding short-term revenue objectives, and sub-permit acreage. Funders have expressed a desire to support Alliance Growers throughout the permit term and beyond.
Under the terms of the Agreement, upon completion of the filing of Audited Financial Statements and the rescission of the cease Trade Order, Alliance Growers will issue a total of 25 million shares at a deemed value of $0.10 per share to the private company as consideration for the acquisition of 70% of the shares of the African company which has been granted the aforementioned Permit.
Alliance Growers has been granted an exemption by the Canadian Securities Exchange regarding its minimum pricing policy. Accordingly, in conjunction with the Agreement and upon completion of the filing of Audited Financial Statements and the rescission of the cease Trade Order, Alliance Growers will undertake a private placement financing of up to $150,000 by way of issuance of up to 6 million Units at a price of $0.025 per Unit. Each Unit is comprised of one common share and one half-share purchase warrant, with each whole warrant entitling the holder to acquire one common share of the Company at a price of $0.05 per share, for a period of two years. The warrants are subject to an acceleration clause after the resale restrictions on the shares have expired. The expiry time of the warrants may be accelerated if the Company’s shares trade at or above a weighted average trading price of $0.15 per share for 10 consecutive trading days. Finders fees may be payable on portions or all the financing, at the rate of up to 10% in cash.
Subsequent News Release
The Company will disseminate a subsequent news release upon closing of the transaction that will provide further disclosure including: the name of the African jurisdictions and where the private company is licensed; further information relating to the private company; biographies on the management and directors of the private company; and the details of the proposed financing to be completed for the transaction.
About Alliance Growers Corp.
Alliance Growers is a Diversified Global Medical Cannabis Company driven by the Company’s ‘Four Pillars’ Organization Plan – Cannabis Biotech Complex (products and services to cultivators), Strategic Investments in Cannabis Cultivators, CBD Oil Supply and Distribution, and Research and Technology.
Alliance Growers is working with Pharmagreen Biotech Inc. to jointly develop and operate a 63,000-square foot Cannabis Biotech Complex, to be the first of its kind in Western Canada to house a DNA Botany lab, CBD extraction facility and Tissue Culture Plantlet Production facility to service the Cannabis market and agriculture market in general.
For further information, please visit the Company’s website at www.alliancegrowers.com or the Company’s profile at www.sedar.com.
If you would like to be added to Alliance Growers’ news distribution list, please send your email address to newsletter@alliancegrowers.com.
For more information contact:
Dennis Petke
CEO, President and Director
Tel: 778-331-4266
DennisPetke@alliancegrowers.com
Rob Grace
Communications Consultant
Tel: 778-998-5431
FOLLOW US:
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE
FORWARD LOOKING INFORMATION
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. More particularly and without limitation, the news release contains forward-looking statements and information relating to Company’s corporate strategy. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general, such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and regulated regulations. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Click here to connect with Alliance Growers (CSE:ACG) for an Investor Presentation.
Cannabis - Will The Fortune 500 Join The Party?
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com).
(TheNewswire)
News Provided by TheNewsWire via QuoteMedia
Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products
Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.
Mirai will assist BevCanna with their entry into the new markets, providing connections to established companies with robust distribution networks. Mirai has significant knowledge and relationships in the wellness products market and has facilitated over $100M in transactions with some of Asia’s largest trading companies and retail chains. The well-known distributor will leverage this extensive experience to rapidly scale the TRACE brand throughout the territories. The initial term of the agreement will be two years, with exclusivity subject to a minimum net revenue of C$1.0M over the course of the term and incentives to reach over C$5.0M during the term.
“We’re in active discussions with a number of distributors, wholesalers, trading companies and retailers to determine the best fit for the TRACE brand in the Japanese and Philippine markets,” said Melise Panetta, President of BevCanna. “Japanese consumers in particular are very health-conscious, and prospective partners have confirmed that the wellness benefits of our TRACE portfolio will be very appealing to this demographic.”
With over 40 years of experience working with some of Asia’s largest corporations, Mirai Marketing was founded by a team of Canadian and Japanese principals who have extensive experience in international sales, management and project development in a range of industries. Mirai is actively focusing on expanding sales of Naturo Group’s beverage and natural wellness products throughout Asia.
“We’re very excited to represent the TRACE products in the Japanese and Philippine marketplaces,” said Hideaki Sakuma, COO of Mirai. “We’ve seen an incredible growth in the demand for wellness-focused products by Asian consumers in recent years and an eagerness to participate in the evolution of health products. The TRACE line is certain to be a strong performer in this emerging market.”
About BevCanna Enterprises Inc.
BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) is a diversified health & wellness, beverage and natural products company. BevCanna develops and manufactures a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients.
With decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale, the team demonstrates an expertise unmatched in the nutraceutical and cannabis-infused beverage categories. Based in British Columbia, Canada, BevCanna owns a pristine alkaline spring water aquifer and a world–class 40,000–square–foot, HACCP certified manufacturing facility, with a bottling capacity of up to 210M bottles annually. BevCanna’s extensive distribution network includes more than 3,000 points of retail distribution through its market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network, and a partnership with #1 U.S. cannabis beverage company Keef Brands .
On behalf of the Board of Directors:
John Campbell, Chief Financial Officer and Chief Strategy Officer
Director, BevCanna Enterprises Inc.
Disclaimer for Forward-Looking Information
This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding: the Company’s agreement with Mirai, including the potential benefits thereof; the Japanese market for TRACE products and that the Company’s products will be very appealing to Japanese consumers; that there has been incredible growth in the demand for wellness-focused products by Japanese consumers in recent years and an eagerness to participate in the evolution of health products; that the TRACE line is certain to be a strong performer in this emerging market; and other statements regarding the business plans of the Company. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements.
Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include, among other things: general market conditions; changes to consumer preferences; volatility of commodity prices; future legislative, tax and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the inability to implement business strategies; competition; currency and interest rate fluctuations; inability to successfully negotiate and enter into commercial arrangements with other parties; and other factors beyond the control of the Company and its commercial partners. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law, and the Company does not assume any liability for disclosure relating to any other company mentioned herein.
Stock Option Grant
In connection with the sales agency distribution agreement with Mirai, the Company has granted (the “Grant”) an aggregate of 1,000,000 stock options (each, an “Option”) to purchase up to 1,000,000 common shares of the Company to Mirai. The Options granted vest upon the achievement of certain sales performance milestones and are exercisable for a period of 25 months from the date of Grant at a price of $1.50 per common share.
None of the securities acquired in the Grant will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005225/en/
For media enquiries or interviews:
Wynn Theriault, Thirty Dash Communications Inc.
416-710-3370
wynn@thirtydash.ca
For investor enquiries:
Bryce Allen, BevCanna Enterprises Inc.
778-766-3744
bryce@bevcanna.com
News Provided by Business Wire via QuoteMedia
Further to its press release dated April 12, 2021, Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that it has oversubscribed and upsized its non-brokered private placement (the “Offering”) due to strong investor demand. The Company now anticipates that the Offering will be completed for gross proceeds of not less than $550,000.00, consisting of not less than 2,910,053 units (“Units”) at a price of $0.189 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one half of one Common Share purchase warrant (a “Warrant”). Each Warrant is exercisable to acquire one Common Share at an exercise price of C$0.38 per Common Share for a period of 36 months from the date of closing of the Offering (the “Closing Date”), scheduled for April 22, 2021. The Units will have a hold period of four months and one day from the date of issuance.
Ayurcann CEO Igal Sudman commented: “We are very pleased with the demand we are seeing for the Offering. The feedback we have received to date is showing that our business is resonating with investors. We’re looking forward to closing the offering and proceeding with the planned Phase 2 build out, which will help greatly increase our facility’s capacity.”
As previously stated, certain insiders of the Company may participate in the Offering. The Company may pay a commission in cash equal to 6% of the value of select proceeds raised under the Financing, specifically excluding any funds raised from insiders.
The Company will use the gross proceeds of the Offering for their Pickering facility Phase 2 expansion, which, when such expansion is complete, is estimated to increase the Company’s annual extraction capacity from 200,000 kgs to 300,000 kgs, and increase the fulfillment capabilities of cannabis 2.0 and 3.0 products from approximately 1 million units annually to approximately 2.5 million units annually.
For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary
Ayurcann Holdings Corp.
Tel: 416-720-6264
Email: igal@xtrx.ca
Investor Relations:
Ryan Bilodeau
Tel: 416-910-1440
Email: ir@ayurcann.com
About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward- looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements, including but not limited to statements relating to the Company’s expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Factors that could cause the actual results to differ materially from those in forward-looking statements include, but are not limited to, failure to obtain regulatory approval, ability to increase production at the Company’s facilities, the continued availability of capital and financing, and general economic, market or business conditions. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that the statements will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, Further, there may be others that cause results not to be as anticipated, estimated or intended and such changes could be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have significant economic and geopolitical impacts that may adversely affect the Company’s business, financial condition and/or results of operations. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Readers should not place undue reliance on the Company’s forward-looking statements.
News Provided by GlobeNewswire via QuoteMedia
UK InstaCoin APP Promises to Open NFTs up to the Masses through Social Media
Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is pleased to provide an update on its recent investment in InstaCoin Technologies Ltd., a newly formed UK entity
Following an extensive testing period, new NFT APP InstaCoin has announced a global submission to the Apple store platforms with imminent release. The APP which promises to simplify the creation of NFT assets from a user’s social media has gone through extensive scale and blockchain testing as well as creating full language compatibility with the Chinese markets and European block.
NFTs are the new and most popular way to sell digital content across the world. Up until now the focus has been on large value sales, InstaCoin APP promises to bring the creation and auction element to the everyday person.
Code has a strong track record with the founders of InstaCoin through the Company’s existing TRAD3R investment. Code is excited to expand their involvement with TRAD3R and InstaCoin, as both entities are taking an innovative approach within the blockchain ecosystem. Code has taken an early 50% equity position of InstaCoin who aims to democratize NFT’s rather than focus primarily on multi-million dollar individual components.
The InstaCoin APP is positioned as the world’s first self-serve social NFT platform. InstaCoin will allow users to connect their social profiles to the blockchain and create instant NFT tokens from their own content. Followers and fans connect in the open market for immediate sales.
InstaCoin Technologies Ltd., a newly formed UK entity, has no relationship with any other company or crypto exchange with similar names, including Instacoin Capital Inc.
About Codebase Ventures Inc.
Codebase Ventures Inc. seeks early-stage investments in emerging technology sectors, including the blockchain ecosystem and fintech. The Company identifies such opportunities and applies its relationships and capital to advance its interests.
For further information, please contact:
George Tsafalas – Ivy Lu
Investor Relations
Telephone: Toll-Free (877) 806-CODE (2633) or 1 (778) 806-5150
E-mail: IR@codebase.ventures
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
SOURCE: Codebase Ventures Inc.
View source version on accesswire.com:
https://www.accesswire.com/640877/Codebase-Investee-Instacoin-NFT-App-UK-Completes-Worldwide-Testing-Phase-and-Submission-to-Apple-Store-Platforms
News Provided by ACCESSWIRE via QuoteMedia